Clinical Trial Update: A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

A Phase I comparative study evaluating pharmacokinetics, safety, and preliminary efficacy of RPH-002 versus cetuximab (Erbitux) in unresectable metastatic or re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• RPH-002

Snippet

Sponsor: R-Pharm | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: COMPLETED